METHOD OF TREATING THE EFFECTS OF STROKE
The present disclosure provides methods of improving cerebral function or preventing loss of cerebral function and/or treating or preventing a movement disorder and/or regenerating cerebral neurons in a subject who has suffered a stroke, the method comprising administering to the subject a population of cells enriched for STRO-1 + cells and/or progeny thereof and/or soluble factors derived therefrom.
1 . A method of regenerating cerebral neurons in a human subject who has suffered a stroke and, or is at risk of having, a movement disorder as a result of the stroke, the method comprising administering to the human subject a population of human cells enriched for STRO-1 + , TNAP + , CD146 + mesenchymal precursor cells and/or culture-expanded progeny thereof.
2 . The method of claim 1 , wherein the cerebral neurons are in the cerebral cortex.
3 . (canceled)
4 . The method of claim 2 , wherein the movement disorder is paralysis, partial paralysis, slurred speech, uncoordinated movement, muscle weakness, hypotonicity, hypertonicity or involuntary abnormal movement.
5 - 6 . (canceled)
7 . The method of claim 1 , wherein the cerebral neurons are in the motor cortex and/or sensory cortex.
8 . The method of claim 1 , wherein the stroke is an ischemic stroke.
9 . The method of claim 8 , wherein the ischemic stroke is caused by an occlusion of a middle cerebral artery in a subject.
10 . The method of claim 1 , wherein the initial administration is performed between 1 hour and 1 month after the stroke.
11 - 13 . (canceled)
14 . The method of claim 1 , wherein the population of cells is derived from bone marrow, adipose tissue, or dental pulp.
15 . The method of claim 1 , wherein the population is administered systemically.
16 . The method of claim 1 , wherein the population enriched is administered locally to the brain of the human subject.
17 - 18 . (canceled)
19 . The method of claim 1 , wherein the population is administered a plurality of times.
20 . The method of claim 19 , wherein the population is administered once every four or more weeks.
21 . The method of claim 1 , comprising administering 0.1×10 6 to 5×10 6 cells and/or progeny thereof per kg.
22 . The method of claim 1 , comprising administering 0.3×10 6 to 2×10 6 STRO-1 + cells and/or progeny thereof per kg.
23 . (canceled)
24 . The method of claim 1 , comprising administering 0.1×10 5 to 0.5×10 6 cells and/or progeny thereof per kg.
25 . The method of claim 1 , wherein the population is allogeneic.
26 . The method of claim 1 , wherein the population has been culture expanded prior to the administration.
27 . The method according to claim 1 , wherein the population was cryopreserved prior to the administration.
28 . The method of claim 1 , wherein the population is autogeneic.
29 . (canceled)